0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Contempo Updates |

The Prospect of Silencing Disease Using RNA Interference

Premlata Shankar, MD; N. Manjunath, MD; Judy Lieberman, MD, PhD
JAMA. 2005;293(11):1367-1373. doi:10.1001/jama.293.11.1367.
Text Size: A A A
Published online

The discovery of RNA interference (RNAi), an endogenous cellular gene-silencing mechanism, has already provided a powerful tool for basic science researchers to study gene function. The subsequent finding that RNAi also operates in mammalian cells has generated excitement regarding potential therapeutic applications. In this article we discuss the basic mechanism of RNAi and the therapeutic opportunities and obstacles for harnessing RNAi for therapy of human disease.

Figures in this Article

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Figure. Mechanism of RNA Interference
Graphic Jump Location

Gene silencing by RNA interference can be initiated by introducing synthetic small interfering RNAs (siRNAs) or their precursors into cells where they are taken up by the endogenous microRNA processing machinery. The siRNA precursors are cleaved by the Dicer enzyme into siRNAs, which are 19- to 21-nucleotide double-stranded RNAs with a 2- to 3-nucleotide overhang and characteristic 5′-phosphate and 3′-hydroxyl groups at each end. As Dicer, an RNAse III–like enzyme, hands off the siRNA to the RISC (the cellular complex ultimately responsible for “slicing” messenger RNA [mRNA]), the double-stranded RNA unwinds, the RISC becomes activated, and 1 strand (the guide strand) remains within the activated complex. If the guide strand is homologous to an mRNA sequence, Argonaute 2, an enzyme within the RISC complex, cleaves the mRNA in the center of the region of homology. The cleaved mRNA is rapidly degraded and the protein for which it encodes is not produced. The guide strand small RNA is protected from degradation by the RISC and can direct the cleavage of many mRNAs. Alternately, plasmids or viral vectors encoding small stem-loop RNAs (called short hairpin RNAs [shRNAs]) can be introduced into cells where they are incorporated into the cell’s genome, resulting in the expression of shRNAs that are processed in the nucleus by the same mechanism as endogenous microRNA precursors and exported to the cytoplasm where they are processed similarly to the process described above.

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 93

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();